Too Old to Operate3d
LUNA 3: Rilzabrutinib Meets Primary Endpoint in ITP
Rilzabrutinib improved efficacy and QOL outcomes among pre-treated adult patients with immune thrombocytopenia.
Pharmaceutical Technology4d
Fostamatinib disodium by Rigel Pharmaceuticals for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology4d
Immune globulin (human) by CSL for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Immune globulin (human) is under clinical development by CSL and currently in Phase III for Chronic Lymphocytic Leukemia (CLL).